Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - cyproterone acetate - oral tablet - 100mg

Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - cyproterone acetate - oral tablet - 100mg

Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

stragen uk ltd - cyproterone acetate - oral tablet - 50mg

Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

stragen uk ltd - cyproterone acetate - oral tablet - 100mg

Australija - anglų - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - nomegestrol acetate, quantity: 2.5 mg; estradiol hemihydrate, quantity: 1.55 mg (equivalent: estradiol, qty 1.5 mg) - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; microcrystalline cellulose; purified talc; lactose monohydrate; colloidal anhydrous silica; titanium dioxide; iron oxide yellow; polyvinyl alcohol; macrogol 3350; iron oxide black - oral contraception.

Malaizija - anglų - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

schmidt biomedtech sdn bhd - cyproterone acetate; ethinylestradiol -

Singapūras - anglų - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - cyproterone acetate; ethinylestradiol - tablet, sugar coated - 2 mg - cyproterone acetate 2 mg; ethinylestradiol 0.035 mg

Airija - anglų - HPRA (Health Products Regulatory Authority)

bayer limited - cyproterone acetate; ethinylestradiol ph.eur. - coated tablet - 2/35 milligram(s) - antiandrogens and estrogens; cyproterone and estrogen

Malaizija - anglų - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

eurodrug laboratories (m) sdn. bhd. - cyproterone acetate; ethinylestradiol -

Australija - anglų - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cyproterone acetate, quantity: 50 mg - tablet, uncoated - excipient ingredients: maize starch; magnesium stearate; povidone; colloidal anhydrous silica; lactose monohydrate; pregelatinised maize starch - women -moderately severe to severe signs of androgenization -moderately severe/severe forms of hirsutism -moderately severe/severe androgen-dependent loss of scalp hair (moderately severe/severe androgenetic alopecia) -moderately severe/severe forms of acne and/or seborrhoea associated with other features of androgenization,cyproterone acetate inhibits the influence of male sex hormones, which are also produced by the female. it is thus possible to treat diseases in women caused either by increased production of androgens or a particular sensitivity to these hormones. hirsutism and alopecia may be expected to recur over a period of time after cessation of treatment.,if cyprone 50 is taken during pregnancy, the properties of the preparation may lead to signs of feminisation in the male foetus. therefore, in women of child bearing potential, pregnancy must be excluded at the commencement of treatment and ethinyl oestradiol taken as well to ensure contraception. this also promotes regular menstruation.,men - reduction of drive in sexual deviations,cyprone 50 reduces the force of the sexual urge in men with sexual deviations. whilst under treatment, the man can control himself better in a predisposing stimulatory situation, but there is no influence on any deviating direction of sexual drive. abnormal patterns of sexual behaviour require treatment when they are distressing to the patient. a prerequisite for therapy is the desire by the patient for treatment.,cyprone 50 therapy should be supplemented by psychotherapeutic and sociotherapeutic measures in order to exploit the period of reduced drive for personal and social re-orientation. - inoperable prostatic carcinoma - to suppress "flare" with initial lhrh analogue therapy - in long-term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred - in the treatment of hot flushes in patients treated with lhrh analogues or who have had orchidectomy